Vascular Therapies touts surgical stenosis treatment trial despite missed primary endpoint

Vascular Therapies announced today that a Phase 3 clinical trial of its Sirogen sirolimus formulation showed encouraging outcomes.

Cresskill, N.J.-based Vascular Therapies designed its Sirogen proprietary sirolimus formulation for intraoperative local drug delivery to reduce surgical stenosis in blood vessels. The Phase 3 clinical trial evaluated Sirogen in elderly end-stage renal disease patients, according to a news release.

Get the full story at our sister site, Drug Delivery Business News.

Read more
  • 0